FindTrial
Sign In

Multigene Profiling for WHO Classification of CNS tumors

Utility of Gliosense, the multigene NGS assay to guide WHO compliant molecular classification of CNS tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037080
Enrollment
300
Registered
2021-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Datar Cancer Genetics Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a)FFPE specimens of the patients diagnosed with CNS tumors. b)Viable tumor content in the block provided >10 %. c)Specimens with prior histopathology and/ immunohistochemistry/molecular/FISH records available. d)Clinical information sheet : Age, gender, site, duration, location, imaging, recurrence (if any).

Exclusion criteria

Exclusion criteria: a)Tumors other than listed CNS tumors. b)Specimens which fail to meet all of the above criteria will be excluded. Failing to meet any single criteria would be sufficient grounds for exclusion. c)Tumor content of the specimens d)Sub-optimally processed blocks.

Design outcomes

Primary

MeasureTime frame
To evaluate the utility of GlioSenseTM assay in guiding WHO complaint molecular classification of CNS tumors.Timepoint: Baseline (Day 0)—

Secondary

MeasureTime frame
To identify novel biomarkers in CNS tumorsTimepoint: Baseline (Day 0)—

Countries

India

Contacts

Public ContactDr Sudha Murthy

Datar Cancer Genetics Private Limited

dadasaheb.akolkar@datarpgx.com02536690804

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026